Alterity Therapeutics Ltd Total Assets
Alterity Therapeutics Ltd total assets. Based on the latest financial reports, Alterity Therapeutics Ltd (ATHE) holds total assets worth $46.02 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ATHE market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Alterity Therapeutics Ltd (1998–2026)
Total assets of Alterity Therapeutics Ltd from 1998 to 2026. This chart illustrates how Alterity Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. See ATHE share price today for real-time trading data and today's change.
Alterity Therapeutics Ltd - Asset Composition Analysis
Alterity Therapeutics Ltd Total Assets Breakdown (June 2026)
Alterity Therapeutics Ltd total assets breakdown as of June 2026. Alterity Therapeutics Ltd's total assets of $46.02 Million consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.1% |
| Accounts Receivable | $7.70 Million | 16.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2026)
This chart illustrates how Alterity Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Alterity Therapeutics Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alterity Therapeutics Ltd's current assets represent 99.6% of total assets in 2026, an increase from 0.0% in 1998.
- Cash Position: Cash and equivalents constituted 81.1% of total assets in 2026, up from 0.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 16.7% of total assets.
Alterity Therapeutics Ltd Competitors by Total Assets
Key competitors of Alterity Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Alterity Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.52 | 12.98 | 10.92 |
| Quick Ratio | 14.52 | 12.98 | 10.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $42.68 Million | $42.34 Million | $30.42 Million |
Alterity Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Alterity Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.71 |
| Latest Market Cap to Assets Ratio | 0.98 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | $46.02 Million |
| Market Capitalization | $44.97 Million USD |
Valuation Analysis
Near Book Valuation: The market values Alterity Therapeutics Ltd's assets close to their book value (0.98x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: Alterity Therapeutics Ltd's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Alterity Therapeutics Ltd (1998–2026)
The table below shows the annual total assets of Alterity Therapeutics Ltd from 1998 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | $46.02 Million | -0.01% |
| 2025-06-30 | $46.03 Million | +139.42% |
| 2024-06-30 | $19.22 Million | -29.63% |
| 2023-06-30 | $27.32 Million | -33.96% |
| 2022-06-30 | $41.36 Million | +23.16% |
| 2021-06-30 | $33.59 Million | +152.43% |
| 2020-06-30 | $13.30 Million | -33.17% |
| 2019-06-30 | $19.91 Million | +6.32% |
| 2018-06-30 | $18.73 Million | -25.93% |
| 2017-06-30 | $25.28 Million | -25.04% |
| 2016-06-30 | $33.73 Million | -19.38% |
| 2015-06-30 | $41.83 Million | +0.46% |
| 2014-06-30 | $41.64 Million | +143.89% |
| 2013-06-30 | $17.07 Million | +132.55% |
| 2012-06-30 | $7.34 Million | -18.52% |
| 2011-06-30 | $9.01 Million | +32.49% |
| 2010-06-30 | $6.80 Million | +47.95% |
| 2009-06-30 | $4.60 Million | -60.79% |
| 2008-06-30 | $11.72 Million | +51.85% |
| 2007-06-30 | $7.72 Million | -25.96% |
| 2006-06-30 | $10.43 Million | -53.03% |
| 2005-06-30 | $22.20 Million | -46.07% |
| 2004-06-30 | $41.16 Million | +151.90% |
| 2003-06-30 | $16.34 Million | -7.10% |
| 2002-06-30 | $17.59 Million | -21.07% |
| 2001-06-30 | $22.29 Million | +6.76% |
| 2000-06-30 | $20.88 Million | +1036.48% |
| 1999-06-30 | $1.84 Million | +821.77% |
| 1998-06-30 | $199.28K | -- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more